Literature DB >> 6362725

Bromopyruvate as an active-site-directed inhibitor of the pyruvate dehydrogenase multienzyme complex from Escherichia coli.

P N Lowe, R N Perham.   

Abstract

Bromopyruvate behaves as an active-site-directed inhibitor of the pyruvate decarboxylase (E1) component of the pyruvate dehydrogenase complex of Escherichia coli. It requires the cofactor thiamin pyrophosphate (TPP) and acts initially as an inhibitor competitive with pyruvate (Ki ca. 90 microM) but then proceeds to react irreversibly with the enzyme, probably with the thiol group of a cysteine residue. E1 catalyzes the decomposition of bromopyruvate, the enzyme becoming inactivated once every 40-60 turnovers. Bromopyruvate also inactivates the intact pyruvate dehydrogenase complex in a TPP-dependent process, but the inhibition is more rapid and is mechanistically different. Under these conditions, bromopyruvate is decarboxylated, and the lipoic acid residues in the lipoate acetyltransferase (E2) component become reductively bromoacetylated. Further bromopyruvate then reacts with the new thiol groups thus generated in the lipoic acid residues, inactivating the complex. If reaction with the lipoic acid residues is prevented by prior treatment of the complex with N-ethylmaleimide in the presence of pyruvate, the mode of inhibition reverts to irreversible reaction with the E1 component. In both types of inhibition of E1, reaction of 1 mol of bromopyruvate/mol of E1 chain is required for complete inactivation, and all the evidence is consistent with reaction taking place at or near the pyruvate binding site.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362725     DOI: 10.1021/bi00296a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Inactivation of pyruvate decarboxylase by 3-hydroxypyruvate.

Authors:  G Thomas; R Diefenbach; R G Duggleby
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

2.  Inhibition of pyruvate dehydrogenase complex activity by 3-bromopyruvate affects blood platelets responses in type 2 diabetes.

Authors:  Anna Michno; Katarzyna Grużewska; Hanna Bielarczyk; Marlena Zyśk; Andrzej Szutowicz
Journal:  Pharmacol Rep       Date:  2020-01-10       Impact factor: 3.024

3.  Inhibition of pyruvate:ferredoxin oxidoreductase from Trichomonas vaginalis by pyruvate and its analogues. Comparison with the pyruvate decarboxylase component of the pyruvate dehydrogenase complex.

Authors:  K P Williams; P F Leadlay; P N Lowe
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

4.  Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester.

Authors:  Zhenjie Tang; Shuqiang Yuan; Yumin Hu; Hui Zhang; Wenjing Wu; Zhaolei Zeng; Jing Yang; Jingping Yun; Ruihua Xu; Peng Huang
Journal:  J Bioenerg Biomembr       Date:  2012-02-18       Impact factor: 2.945

5.  Alkylation of acetohydroxyacid synthase I from Escherichia coli K-12 by 3-bromopyruvate: evidence for a single active site catalyzing acetolactate and acetohydroxybutyrate synthesis.

Authors:  P M Silverman; L Eoyang
Journal:  J Bacteriol       Date:  1987-06       Impact factor: 3.490

6.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Jean-Francois H Geschwind; Rani Kunjithapatham; Manon Buijs; Josephina A Vossen; Irina Tchernyshyov; Robert N Cole; Labiq H Syed; Pramod P Rao; Shinichi Ota; Mustafa Vali
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

Review 7.  Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment.

Authors:  Tengjiao Fan; Guohui Sun; Xiaodong Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

8.  Revealing Donor Substrate-Dependent Mechanistic Control on DXPS, an Enzyme in Bacterial Central Metabolism.

Authors:  Melanie L Johnston; Caren L Freel Meyers
Journal:  Biochemistry       Date:  2021-03-04       Impact factor: 3.162

9.  The effect of MEP pathway and other inhibitors on the intracellular localization of a plasma membrane-targeted, isoprenylable GFP reporter protein in tobacco BY-2 cells.

Authors:  Michael Hartmann; Andrea Hemmerlin; Elisabet Gas-Pascual; Esther Gerber; Denis Tritsch; Michel Rohmer; Thomas J Bach
Journal:  F1000Res       Date:  2013-08-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.